Adamis provides update on the phase 2/3 trial of tempol in covid-19 positive high-risk subjects

San diego, sept. 21, 2022 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp) today announced that the third planned interim analysis of the phase 2/3 clinical trial examining the effects of tempol in high risk subjects with early covid-19 infection did not achieve its primary endpoint, as measured by comparing the rate of sustained clinical resolution of symptoms of covid-19 at day 14 of tempol versus placebo. the independent data safety monitoring board (dsmb) recommended that the study be halted early due to lack of efficacy. the dsmb did note that no safety concerns were identified in the subjects that received tempol. based on the recommendation from the dsmb, the company has halted the trial and will now evaluate the unblinded data from the trial to determine the next developmental steps for tempol.
ADMP Ratings Summary
ADMP Quant Ranking